Therapeutic progresses of hepatitis C.

被引：0

作者：

马巧玉 ^{[1
]}

机构：

[1] 第三军医大学西南医院全军感染病研究所 400038重庆

来源：

中华肝脏病杂志 | 2003年 / 08期

关键词：

肝炎病毒; 丙型; 治疗学;

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

100401 ;

摘要：

全世界约有4千万慢性丙型病毒性肝炎(简称丙肝)患者。虽然丙肝进展缓慢,但在美国,每年仍有800～1200名患者由丙肝、肝硬化进展成肝细胞肝癌而至死亡,且比例呈上升趋势。丙肝的治疗已有十余年的历史,90年代初,单独用干扰素(interferon,IFN)治疗,仅有不到10％的丙肝患者获得持续性肝功能改善和病毒阴转,远期疗效不佳。近来,丙肝治疗的进展主要是IFN加口服利巴韦林(病毒唑),这两种药物合用6～12个月,持续病毒应答率可达30％～40％。目前食品及药物管理局(Food and Drug Administration,FDA)推荐长效pegylatedIFN与利巴韦林联合应用,可将丙肝患者持续性病毒应答率提高至50％以上。

引用

页码：55 / 56

页数：2

共 12 条

[1] Natural history of clinically compensated hepatitis C virus-related cirrhosis after liver transplantation. Berenguer M,Prieto M,Rayon JM,et al. Hepatology . 2000
[2] Meta-analysis of interferon randomized trials in the treatment of virual hepatitis C: effects of dose and duration. Poynard T,Leroy V,Cohard M,et al. Hepatology . 1996
[3] Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. McHutchison JG,Poynard I. Seminars in Liver Disease . 1999
[4] New therapeutic strategies for hepatitis C. Bisceglie AMD,McHutchison J,Rice CM. Hepatology . 2002
[5] Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled studies. Schalm SW,Weiland O,Hansen BE,et al. Gastroenterology . 1999
[6] Effcacy and safety of peginterferon alfa-2a compared with interferon alfa-2a in noncirrhotic patients with hepatitis C. Reddy KR,Wright TL,Pockros PJ,et al. Hepatology . 2001
[7] Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Bodenheimer HC,Lindsay KL,Davis GL,et al. Hepatology . 1997
[8] Current treatment for chronic hepatitis C. Gary L,Davis MD. Reviews in Gastroenterological Disorders . 2002
[9] Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C: relapsed and treatment-naive patients. Maddrey WC. Seminars in Liver Disease . 1999
[10] Pegylated interferon alfa-2a (Pegasys) in combination with ribavirin: efficacy and safety results from a phase Ⅲ, randomized, acitively controlled, multicenter study. Fried MW,Shiffman ML,Reddy KR,et al. Gastroenterology . 2001

← 1 2 →